{"url_path":"/sec/tngx/8-k/2026-08-11/item-2-02","section_key":"item-2-02","section_title":"Item 2.02 Results of Operations and Financial Condition.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-08-11","source_url":"https://www.sec.gov/Archives/edgar/data/1819133/0001193125-26-343434-index.html","accession_number":"0001193125-26-343434","cik":"0001819133","ticker":"TNGX","issuer_name":"Tango Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1819133/0001193125-26-343434-index.html","primary_entity_key":"0001819133","primary_entity_name":"Tango Therapeutics, Inc."},"word_count":149,"has_tables":true,"body_markdown":"Item 2.02 Results of Operations and Financial Condition.\n\n \n\nOn August 11, 2026, Tango Therapeutics, Inc. issued a press release relating to its results of operations and financial condition for the quarter ended June 30, 2026. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.\n\n \n\nThe press release, and the information set forth therein (including Exhibit 99.1), is being furnished pursuant to Item 2.02 of this Current Report on Form 8-K and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section. Nor shall such document be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in the filing unless specifically stated so therein."}